- Home
- SLGL vs BCAB Comparison
SLGL vs BCAB Comparison
Compare SLGL & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLGL
- BCAB
- Stock Information
- Founded
- SLGL 1997
- BCAB 2007
- Country
- SLGL Israel
- BCAB United States
- Employees
- SLGL N/A
- BCAB N/A
- Industry
- SLGL Biotechnology: Pharmaceutical Preparations
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- SLGL Health Care
- BCAB Health Care
- Exchange
- SLGL Nasdaq
- BCAB Nasdaq
- Market Cap
- SLGL 19.3M
- BCAB 22.3M
- IPO Year
- SLGL 2018
- BCAB 2020
- Fundamental
- Price
- SLGL $8.14
- BCAB $0.38
- Analyst Decision
- SLGL Buy
- BCAB Buy
- Analyst Count
- SLGL 1
- BCAB 2
- Target Price
- SLGL $40.00
- BCAB $1.00
- AVG Volume (30 Days)
- SLGL 25.4K
- BCAB 541.7K
- Earning Date
- SLGL 08-15-2025
- BCAB 08-07-2025
- Dividend Yield
- SLGL N/A
- BCAB N/A
- EPS Growth
- SLGL N/A
- BCAB N/A
- EPS
- SLGL N/A
- BCAB N/A
- Revenue
- SLGL $12,103,000.00
- BCAB $11,000,000.00
- Revenue This Year
- SLGL N/A
- BCAB N/A
- Revenue Next Year
- SLGL $31.17
- BCAB N/A
- P/E Ratio
- SLGL N/A
- BCAB N/A
- Revenue Growth
- SLGL 603.66
- BCAB N/A
- 52 Week Low
- SLGL $3.34
- BCAB $0.24
- 52 Week High
- SLGL $16.50
- BCAB $2.53
- Technical
- Relative Strength Index (RSI)
- SLGL 63.80
- BCAB 44.12
- Support Level
- SLGL $6.96
- BCAB $0.36
- Resistance Level
- SLGL $7.48
- BCAB $0.42
- Average True Range (ATR)
- SLGL 0.28
- BCAB 0.03
- MACD
- SLGL 0.07
- BCAB -0.00
- Stochastic Oscillator
- SLGL 95.88
- BCAB 29.75
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.